Evidence map›Paper›PMID 22134702›Full record

ArticleMolecular and cellular biochemistry2012

Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings.

Iordanis Mourouzis, Polixeni Mantzouratou, Georgios Galanopoulos, Erietta Kostakou, Nikolaos Roukounakis, Alexandros D Kokkinos, Dennis V Cokkinos, Constantinos Pantos

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02512978 (Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction), which is not on this map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02512978 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction

TypeinterventionalSponsorChinese Academy of Medical Sciences, Fuwai HospitalRan2015 to 2019Enrolled160ConditionsMyocardial Infarction, HypothyroidismArmsLevothyroxine
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 60 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Red Araça (Biomedicines · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence.International journal of environmental research and public health · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Iordanis MourouzisDepartment of Pharmacology, University of Athens, 75 Mikras Asias Ave, 11527 Goudi, Athens, Greece.
Polixeni Mantzouratou
Georgios Galanopoulos
Erietta Kostakou
Nikolaos Roukounakis
Alexandros D Kokkinos
Dennis V Cokkinos
Constantinos Pantos
National and Kapodistrian University of Athens · GRAcademy of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study explored the effects of thyroid hormone (TH) treatment on post-ischemic cardiac function and potential implicated mechanisms. Acute myocardial infarction (AMI) was induced in mice by coronary artery ligation while sham-operated animals served as controls. This procedure resulted in a marked depression of cardiac function and significant reduction in TH levels in plasma. TH was given at a dose aiming to normalize T3 levels in plasma [AMI-TH (A)] and also at higher doses. The group of animals treated with the highest dose of TH, which displayed significantly increased mortality rate was included in the study [AMI-TH (B)]. In AMI-TH (A) mice, TH significantly improved left ventricular (LV) ejection fraction (EF%), [27.9% (1.4) in AMI versus 38.0 (3.1) in AMI-TH (A), P < 0.05], and favorably remodeled LV chamber while α-MHC was the dominant isoform expressed. In AMI-TH (B) mice, TH treatment resulted in increased mortality as compared to untreated mice (73% vs 47%, P < 0.05), while the favorable effect of TH was not evident in the survived animals. At the molecular level, TH, at the replacement dose, modestly increased p-Akt levels in the myocardium without any change in p-ERK levels. On the contrary, TH at the higher dose resulted in further increase in p-Akt along with an increase in p-ERK levels. In conclusion, TH appears to have a dose-dependent bimodal effect on post-ischemic cardiac performance and this effect may, at least in part, be mediated by a distinct pattern of activation of Akt and ERK signaling.

Indexed as

Hormone Replacement TherapyAnimalsDisease Models, AnimalDose-Response Relationship, DrugExtracellular Signal-Regulated MAP KinasesHeart RateMaleMiceMice, Inbred C57BLMyocardial ContractionMyocardial InfarctionMyocardiumMyosin Heavy ChainsPhosphorylationProto-Oncogene Proteins c-aktSignal TransductionExtracellular Signal-Regulated MAP KinasesMyh7 protein, mouseMyosin Heavy ChainsProto-Oncogene Proteins c-aktThyroxineTriiodothyronine

Identifiers

PMID22134702
OpenAlexW2054501810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.